Tag: fund

In the news release, Standard Bots Raises $200 Million Series C at $1 Billion Valuation to Scale American-Made, AI-Native Industrial Robots, issued 09-Jun-2026 by...

Experts Share Advice on How to Keep Kids Engaged and Enjoying Family Time on the WaterORLANDO, Fla., June 11, 2026 /PRNewswire/ -- Family boating adventures...

Experts Share Advice on How to Keep Kids Engaged and Enjoying Family Time on the WaterORLANDO, Fla., June 11, 2026 /PRNewswire/ -- Family boating...

Industry veterans bring deep expertise in advanced reactor deployment, nuclear operations and regulatory licensing to support company’s U.S. growth

Industry veterans bring deep expertise in advanced reactor deployment, nuclear operations and regulatory licensing to support company’s U.S. growth

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/VANCOUVER, BC, June 11, 2026 /CNW/ - Helius Minerals Limited...

From living longer to living free, people across Asia prioritize health and financial self-sufficiency to pursue independence and avoid burdening loved onesHONG KONG, June...

From living longer to living free, people across Asia prioritize health and financial self-sufficiency to pursue independence and avoid burdening loved onesHONG KONG, June...

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

Toobit unveils Prediction Market, allowing traders to hedge risk and profit from crypto, financial, and global event forecasts using USDT.

A $2.7 trillion deposit. A company worth less than $1 billion. And a government that is already moving.

A $2.7 trillion deposit. A company worth less than $1 billion. And a government that is already moving.

Defiance ETFs to Launch SPCU, The 2X SpaceX ETF, as the SpaceX (SPCX) IPO Nears

Scholarship aims to support students of color pursuing careers in dentistry to improve access to representative oral care across the state. SEATTLE, June 10,...